flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
500 vacancies in the Flemish biotech sector
Over 300 businesses active in the Flemish biotech or life sciences cluster possess 500 open vacancies, in particular for job profiles in production, e.g. (bio)engineers, industrial chemists or ICT experts. In addition, the sector is looking for new staff for research and development. Flanders is among the five most important life sciences clusters in Europe. Here, the cluster provides direct employment to over 20,000 people and indirectly to a further 80,000. That's according to research by flanders.bio and KBC Securities. The figures were made public within the framework of 'knowledge for growth', the annual congress of the biotech and life sciences cluster in Flanders.
argenx announces closing of NASDAQ IPO
argenx (Euronext & Nasdaq: ARGX), announced today the closing of its initial public offering in the United States (the "Offering") of 6,744,750 American Depositary Shares ("ADSs"), at a price to the public of $17.00 per ADS, for gross proceeds of approximately $114.7 million. This includes the full exercise of the underwriters' option to purchase additional ADSs. Each of the ADSs offered represents the right to receive one ordinary share.
ThromboGenics NV to present THR-317 Pre-clinical Research Findings
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will give a presentation at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting, which is being held in Budapest, Hungary from May 25-27.
Innovative software Moon autonomously diagnoses rare diseases within minutes
Diploid, a Leuven-based genomics startup, announces the release of Moon, the first software package that autonomously diagnoses rare diseases using artificial intelligence. Moon reduces the time for genome interpretation from hours or days to mere minutes, making it the world’s fastest software for rare disease diagnostics. Moon has been tested by the University of Antwerp (UZA) in Belgium and by the National Institutes of Health (NIH) in Bethesda, USA.